Abstract. Ovarian cancer is the most common gynecological malignancy. At present, cisplatin is used to treat ovarian cancer; however, the development of cisplatin resistance during therapy is a common obstacle to achieving favorable outcomes. Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. In this study, we observed the cytoplasmic and mitochondrial levels of Ca 2+ by confocal laser microscopy. We also detected cell apoptosis using western blot analysis and flow cytometry. The present study demonstrated that TAT-fused inositol 1,4,5-trisphosphate receptor-derived peptide (TAT-IDP S ), which targets the BH4 domain of Bcl-2, increased cisplatin-induced Ca 2+ flux from the endoplasmic reticulum (ER) into the cytosol and mitochondria. In addition, TAT-IDP S increased cisplatin-induced expression of mitochondrial apoptosis-associated proteins and ER stress-associated proteins. These results indicated that TAT-IDP S may enhance the cytotoxicity of cisplatin toward ovarian carcinoma cells by increasing ER Ca 2+ release.
Introduction
Ovarian cancer is the most common form of gynecological cancer and is a serious threat to women's health and survival worldwide. Cis-diammine-dichloroplatinum (II), also known as cisplatin, is a classic chemotherapy drug that is widely used for the treatment of advanced cancers, including ovarian cancer (1, 2) . Cisplatin exhibits a satisfactory therapeutic effect during the early stages of administration; however, patients often become resistant to cisplatin during long-term administration. It has previously been reported that overexpression of the anti-apoptotic B-cell lymphoma 2 (Bcl-2) protein facilitates the pathophysiology and cisplatin resistance of cancer by inhibiting apoptosis (3). Bcl-2 contains BH1, BH2, BH3 and BH4 domains. Bcl-2 has been reported to bind to Bcl-2-associated X protein (Bax)/Bcl-2 homologous antagonist killer via its BH3 domain and inhibit cytochrome c release from the mitochondria, thus maintaining mitochondrial integrity. Notably, BH3-mimetic Bcl-2 inhibitors have attracted much attention and have been extensively studied (4) . The BH3-mimetics ABT737 and ABT-263 have been reported to enhance cisplatin sensitivity in cholangiocarcinoma and ovarian carcinoma cells (5, 6) . However, the function of the Bcl-2 BH4 domain in ovarian carcinoma cells remains unclear.
Bcl-2 has been reported to induce a reduction in endoplasmic reticulum (ER) Ca 2+ load and release via its BH4 domain (7) . The ER is the main store of intracellular Ca 2+ and a crucial organelle in eukaryotic cells. A large release of Ca 2+ from the ER can activate calpain-1, which is a Ca 2+ -dependent cysteine protease responsible for the transition from caspase-4 to cleaved caspase-4, which in turn activates ER stress-induced apoptosis (8) . Furthermore, Ca 2+ release from the ER can enhance mitochondrial Ca 2+ uptake, which is accompanied by a release of cytochrome c and activation of the mitochondrial apoptotic pathway (9) . In our previous study, it was demonstrated that the expression of Bcl-2 was higher in cisplatin-resistant SKOV3/DDP ovarian cancer cells compared with in cisplatin-sensitive SKOV3 ovarian cancer cells (10) . A low dose of cisplatin induced apoptosis, which was accompanied by cytoplasmic and mitochondrial Ca 2+ overload in SKOV3 cells, but not in SKOV3/DDP cells (11 , combined with chemotherapy, may be considered a viable treatment strategy for the prevention and treatment of ovarian cancer. Cell lines. Cisplatin-resistant ovarian cancer SKOV3/DDP cells were obtained from the Chinese Academy of Medical Sciences (Beijing, China) and Peking Union Medical College (Beijing, China). Cells were cultured at 37˚C in an atmosphere containing 5% CO 2 in RPMI-1640 culture medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.). Cisplatin-resistant SKOV3/DDP cells were maintained in medium containing 1 µg/ml cisplatin (Sigma-Aldrich; Merck KGaA) for 24 h to maintain resistance.
Materials and methods

Antibodies
Cell viability assays. Cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. SKOV3/DDP cells were seeded into 96-well culture plates in 100 µl medium at a density of 1x10 4 cells/well. After 2 days, agents [cisplatin (15 µg/ml) and/ or TAT-IDPS (25 µM) in the presence or absence of 50 µM 2-APB] were added to quadruplicate wells and incubated for 24 or 48 h at 37˚C. For the MTT assay (Beyotime Institute of Biotechnology, Shanghai, China), 20 µl/well MTT (5 mg/ml in PBS) was added to each well; after 4 h at 37˚C, dimethyl sulfoxide (150 µl/well; Beijing Chemical Industry Group Co., Beijing, China) was added and the plates were agitated at room temperature for 10 min. Absorbance was measured at a wavelength of 570 nm using a microplate reader (BioTek Instruments, Inc., Winooski, VT, USA).
Western blotting. Whole-cell protein extracts were isolated from SKOV3/DDP cells using cell lysis buffer [50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 1 mM sodium-EDTA, 1 mM EDTA; 1% (v/v) Triton X-100; 2.5 mM sodium pyrophosphate; 1 mM β-glycerophosphate; 1 mM Na 3 VO 4 ; 1 mM NaF; 1 µg/ml leupeptin and 1 mM phenylmethylsulfonyl fluoride] for western blotting. Protein concentration was quantified using the Quick Start Bradford protein assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). For western blot analysis, lysates (30 µg) were separated by 10% (w/v) SDS-PAGE and were transferred onto immobilon-P transfer membranes (EMD Millipore, Billerica, MA, USA). The membranes were blocked with 5% (w/v) non-fat dry milk in buffer [10 mM Tris-HCl (pH 7.6), 100 mM NaCl, and 0.1% Tween-20] for 1 h at room temperature and were then incubated with the desired primary Abs [caspase-3 (dilution, 1:200); caspase-4 (dilution, 1:200); cleaved caspase-4 (dilution, 1:200); cleaved caspase-3 (dilution, 1:1,000); PDI (dilution, 1:1,000); CHOP (dilution, 1:1,000); β-actin (dilution, 1:2,000); Bax (dilution, 1:1,000); cytochrome c (dilution, 1:1,000); calpain-1 (dilution, 1:200)] overnight at 4˚C, followed by incubation with horseradish peroxidase-conjugated secondary Abs (dilution, 1:2,000) for 1.5 h at room temperature. Immunodetection was performed using enhanced chemiluminescence reagents (PE0010-b; Solarbio, New York, NY, USA) and images were captured using Syngene Bio Imaging (Syngene, Cambridge, UK). Protein expression levels were normalized to those of β-actin and the ratios of normalized protein to β-actin are presented as the mean ± standard deviation from three independent experiments. Protein expression levels were semi-quantified by densitometry using Quantity One software (version 4.6.9; Bio-Rad Laboratories, Inc.).
Immunofluorescence staining and confocal laser microscopy. Cells (4x10 4 cells/well) were cultured on coverslips overnight, following treatment with increasing doses of cisplatin (5, 10 and 15 µg/ml) for 24 h at 37˚C, and were fixed with 4% (w/v) paraformaldehyde and stained with nuclear Hoechst 33342 (1 µg/ml; Sigma-Aldrich; Merck KGaA) for 5 min. Subsequently, the cells were washed with PBS and were examined under an Olympus FV1000 confocal laser microscope (Olympus Corporation, Tokyo, Japan) to reveal cell chromatin condensation. The expression of calpain-1 was examined by indirect immunofluorescence. Cells (4x10 4 cells/ well) were cultured on coverslips overnight, and were then treated with the indicated dose of cisplatin with or without TAT-IDP S for 24 h at 37˚C, after which the cells were rinsed with PBS three times. Subsequently, cells were fixed with 4% (w/v) paraformaldehyde for 20 min, permeabilized with 0.1% (v/v) Triton X-100 for 5 min, blocked with bovine serum albumin (PA129262; Thermo Fisher Scientific, Inc.), and incubated with anti-calpain-1 (dilution, 1:100) overnight at 4˚C. Cells were then incubated with Alexa Fluor 488 donkey anti-rabbit IgG (#R37602, 1:400 dilution; Invitrogen; Thermo Fisher Scientific, Inc.) for 30 min at room temperature, stained with Hoechst 33342 (1 µg/ml) for 5 min at room temperature, and washed with PBS three times. After mounting, cells were examined under an Olympus FV1000 confocal laser microscope (Olympus Corporation). The same parameters of illumination and detection were maintained digitally throughout the experiments.
Calcium concentration analysis. The Ca
2+ -sensitive fluorescent dyes Fluo-4/AM (Molecular Probes; Thermo Fisher Scientific, Inc.) and Rhod-2/AM (AAT Bioquest, Sunnyvale, CA, USA) were used to measure Ca 2+ concentration according to the manufacturers' protocols. Prior to exposure to various experimental conditions, the cells were incubated with Fluo-4/AM or Rhod-2/AM for 30 min at 37˚C. Cell samples were then analyzed by confocal laser microscopy. All experiments were performed in triplicate. 
Mitochondrial membrane potential (ΔΨm).
Alterations in ΔΨm during the early stages of apoptosis were assessed using the Muse ® MitoPotential assay (MCH 100110; EMD Millipore). SKOV3/DDP cells were treated with cisplatin alone or in combination with TAT-IDP S . Subsequently, cells were centrifuged at 3,000 x g for 5 min at room temperature, and the cell pellet was suspended in assay buffer (1x10 5 cells/100 µl). MitoPotential dye working solution was added, and the cell suspension was incubated at 37˚C for 20 min. (Fig. 1) .
TAT-IDP S increases cisplatin-induced apoptosis of SKOV3/DDP cells. To evaluate the effects of TAT-IDP
S on cisplatin-induced growth inhibition and apoptosis, SKOV3/DDP cells were treated with cisplatin (15 µg/ml) and/or TAT-IDP S (25 µM) for 24 h and growth inhibition was examined using MTT assays. The results indicated that cisplatin induced growth inhibition in SKOV3/DDP cells. In addition, cotreatment with cisplatin and TAT-IDP S increased the growth inhibitory effects of cisplatin, whereas TAT-IDP S alone had no effect on cell viability compared with in the control group ( Fig. 2A) . Under an optical microscope, it was demonstrated that SKOV3/DDP cells treated with cisplatin became round and fragmented compared with the control cells and that TAT-IDP S enhanced this effect (Fig. 2B) . Furthermore, flow cytometric analysis demonstrated that the rate of apoptosis in SKOV3/DDP cells treated with cisplatin and TAT-IDP S was higher than that in cells treated with cisplatin alone (Fig. 2C and D) . These results suggested that TAT-IDP S increased cisplatin-induced growth inhibition and apoptosis of SKOV3/DDP cells.
TAT-IDP S increases cisplatin-induced ER stress-associated apoptosis by increasing calpain-1 expression in SKOV3/DDP
cells. Since calpain-1, which is a ubiquitous protease, can be activated by cytoplasmic Ca 2+ elevation (16), the present study detected the expression of calpain-1 using confocal microscopy. The results indicated that cotreatment with cisplatin and TAT-IDP S for 24 h increased cisplatin-induced calpain-1 accumulation (Fig. 3A) . Calpain-1 has been reported to enhance ER-associated apoptosis by cleaving its protein substrates (16) . Subsequently, the present study investigated whether TAT-IDP S may sensitize SKOV3/DDP cells to cisplatin-induced ER stress-associated apoptosis. The expression levels of the following ER stress-associated apoptotic proteins: Calpain-1, PDI, CHOP and cleaved caspase-4, were detected by western blot analysis. Cisplatin induced the expression of all four proteins; furthermore, combined treatment with TAT-IDP S enhanced these effects ( Fig. 3B and C) . These results suggested that TAT-IDP S may increase cisplatin-induced ER stress-associated apoptosis of SKOV3/DDP cells by increasing calpain-1 expression.
TAT-IDP S increases cisplatin-induced mitochondria-mediated apoptosis of SKOV3/DDP cells. Mitochondrial Ca
2+
overload can lead to opening of the mitochondrial inner membrane permeability transition pore (MPTP) and can subsequently induce aberrant dissipation of ΔΨm, thus resulting in cell apoptosis. Since an alteration in ΔΨm is considered an early event in apoptosis (17) , the present study monitored the effects of TAT-IDP S and/or cisplatin on ΔΨm at 6 h. SKOV3/DDP cells were treated with cisplatin (15 µg/ml) and/or TAT-IDP S (25 µM) for 6 h, and alterations in ΔΨm were determined using flow cytometry. TAT-IDP S enhanced the cisplatin-induced decrease in ΔΨm (Fig. 4A and B) . Finally, the expression levels of mitochondrial apoptosis-associated proteins (cytochrome c, Bcl-2, Bax and cleaved caspase-3) were detected using western blotting. The results indicated that cotreatment with cisplatin and TAT-IDP S for 24 h increased the cisplatin-induced Bax/Bcl-2 ratio, and the cisplatin-induced expression of cytochrome c and cleaved caspase-3 ( Fig. 4C and D) . These results suggested that TAT-IDP S may further reduce the decrease in ΔΨm induced by cisplatin, which may subsequently contribute to mitochondria-mediated apoptosis of SKOV3/DDP cells.
2-APB reduces the growth inhibition and apoptosis induced by cotreatment with TAT-IDP
S and cisplatin. To further confirm that mitochondrial Ca 2+ overload caused by cotreatment with TAT-IDP S and cisplatin derives from the ER, cells were treated with 2-APB, an IP3R antagonist (18) . Cisplatin and TAT-IDP S -induced mitochondrial Ca 2+ elevation in SKOV3/DDP cells was markedly reduced in the presence of 2-APB (Fig. 5A ). In addition, 2-APB reduced the decrease in ΔΨm induced by cisplatin and TAT-IDP S ( Fig. 5B and C) . Similarly, cisplatin and TAT-IDP S -induced growth inhibition and apoptosis of SKOV3/DDP cells was markedly reduced in the presence of 2-APB (Fig. 5D-F) . Taken together, these results strongly indicated that mitochondrial Ca 2+ overload caused by cotreatment with TAT-IDP S and cisplatin was derived from the ER.
Discussion
Bcl-2 is an anti-apoptotic protein that promotes cell survival predominantly by inhibiting the release of cytochrome c from the mitochondria via its BH3 domain. In addition, Bcl-2 inhibits cell apoptosis by reducing Ca 2+ release from the ER via its BH4 domain. Recently, targeting the BH3 and BH4 domains to generate Bcl-2 inhibitors for cancer therapy has attracted attention. Obatoclax is a BH3 mimetic that can induce apoptosis of numerous types of cancer cell by interacting with the Bcl-2 BH3 domain; this agent has been tested in a phase II clinical trial in patients (19) . Furthermore, Deng et al reported that BDA-366, which is an antagonist of the Bcl-2 BH4 domain, can induce apoptosis of human myeloma U266 cells (20) . The results of the present study demonstrated that by targeting BH4, TAT-IDP S increases cisplatin-induced apoptosis of SKOV3/DDP cells (Fig. 2) . As a major intracellular Ca 2+ store, the ER serves a central role in intracellular Ca 2+ signal transduction, and controls cell death and survival. The release of large amounts of Ca 2+ from the ER promotes cell apoptosis by affecting cytoplasmic and mitochondrial Ca 2+ homeostasis. There is strong evidence to suggest that Bcl-2 directly inhibits proapoptotic Ca 2+ release from IP3R at the ER into the cytoplasm and mitochondria via its BH4 domain (21-23). TAT-IDP S can reverse the Bcl-2-mediated inhibition of IP3-dependent Ca 2+ elevation by targeting the BH4 domain, subsequently triggering Ca 2+ -dependent apoptosis or increasing sensitivity toward proapoptotic stimuli (15) . The present study clearly demonstrated that TAT-IDP S increased cisplatin-induced cytoplasmic and mitochondrial Ca 2+ elevation (Fig. 1) . Elevation of cytoplasmic Ca 2+ levels can lead to activation of a series of Ca 2+ -sensitive enzymes. Calpain-1 is the target of cytoplasmic Ca 2+ , which was originally termed µ-calpain based on the Ca 2+ concentration (µM range) required for its optimal activity (24) . Calpain-1 also participates in the apoptotic pathway triggered by ER stress. Matsuzaki et al confirmed that Ca 2+ -dependent calpain activation promoted neural cell death by inducing the processing and activation of caspase-4 (25) . According to the results of confocal microscopy and western blot analyses, the present study revealed that TAT-IDP S increased cisplatin-induced calpain-1 expression (Fig. 3) and increased cisplatin-induced ER stress-associated apoptosis of SKOV3/DDP cells.
Mitochondria are exposed to high Ca 2+ concentrations following the release of Ca 2+ from the ER. Accumulation of Ca 2+ in the mitochondrial matrix can lead to opening of the MPTP, which in turn causes mitochondrial swelling and rupture, accompanied by dissipation of ΔΨm (26) (27) (28) . The ΔΨm collapse further induces rupture of the outer membrane and subsequent release of mitochondrial apoptotic factors, including cytochrome c, into the cytosol, finally leading to cell apoptosis (29, 30) . Our previous study demonstrated that mitochondrial Ca 2+ levels are closely associated with cisplatin resistance in ovarian carcinoma cells (11) . The present study demonstrated that TAT-IDP S increased cisplatin-induced ΔΨm collapse and mitochondrial-mediated apoptosis of SKOV3/DDP cells. Using 2-APB to effectively block ER Ca 2+ release, the present study further confirmed that TAT-IDP S and cisplatin-induced mitochondrial Ca 2+ overload is derived from the ER (Fig. 5A ).
In conclusion, the results of the present study indicated that TAT-IDP S increased the cisplatin-induced elevation of cytoplasmic and mitochondrial Ca 2+ , which further increased cisplatin-induced ER stress-mediated apoptosis by increasing calpain-1 expression and activating the mitochondrial apoptotic pathway. These results suggested that Ca 2+ release from the ER may regulate cisplatin-induced SKOV3/DDP cell apoptosis, providing a rationale for drugs that specifically disrupt the Bcl-2-IP3R interaction as a novel tool for the treatment of ovarian cancer.
